Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now it's ...

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...

A Dutch biotech cre­at­ing nasal sprays to pro­tect against the flu and coro­n­avirus has raised an ad­di­tion­al $70 ...

Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

A2 Bio­ther­a­peu­tics has raised $80 mil­lion to run three ex­per­i­men­tal CAR-T pro­grams for sol­id tu­mor can­cers. The ...

Biopharma leaders head to San Francisco's JP Morgan Healthcare Conference amid hopes for M&A deals after slow 2024, which saw ...

Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...

Sutro scale-up, Pharma mergers, FDA warnings to Indian firms, new Egypt facility, and UPS acquires Frigo-Trans ...

There's a shopping bonanza for new obesity medicines going on among a marquee cohort of biopharma investors who are ...

Lon­za’s Synaf­fix has se­cured two sep­a­rate li­cens­ing deals with Boehringer In­gel­heim and Japan­ese drug­mak­er ...

Novo Holdings co-leads €32M Series A for Coave Therapeutics, which is developing gene therapies with its ALIGATER technology.